BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention. METHODS: Pediatric patients (n = 120) with ALL (diagnosed 2011-2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models. RESULTS: Participants (57.5% male and 79.1% Hispanic or non-Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short-term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention. CONCLUSIONS: Our findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long-term neurocognitive performance. Sleep and fatigue may be targets for intervention to preserve cognitive functioning in survivors.
BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention. METHODS: Pediatric patients (n = 120) with ALL (diagnosed 2011-2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models. RESULTS: Participants (57.5% male and 79.1% Hispanic or non-Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short-term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention. CONCLUSIONS: Our findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long-term neurocognitive performance. Sleep and fatigue may be targets for intervention to preserve cognitive functioning in survivors.
Authors: Belinda N Mandrell; Jie Yang; Mary C Hooke; Chong Wang; Jami S Gattuso; Marilyn Hockenberry; Heather Jones; Sue Zupanec; Pamela S Hinds Journal: J Pediatr Oncol Nurs Date: 2011-08-15 Impact factor: 1.636
Authors: Bernward Zeller; Christian K Tamnes; Adriani Kanellopoulos; Inge K Amlien; Stein Andersson; Paulina Due-Tønnessen; Anders M Fjell; Kristine B Walhovd; Lars T Westlye; Ellen Ruud Journal: J Clin Oncol Date: 2013-04-15 Impact factor: 44.544
Authors: Michelle N Edelmann; Kevin R Krull; Wei Liu; John O Glass; Qing Ji; Robert J Ogg; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Wilburn E Reddick Journal: Brain Date: 2014-08-13 Impact factor: 13.501
Authors: Pamela S Hinds; Jie Yang; Jami S Gattuso; Marilyn Hockenberry; Heather Jones; Sue Zupanec; Chenghong Li; Valerie McLaughlin Crabtree; Belinda N Mandrell; Robert A Schoumacher; Kelly Vallance; Stacy Sanford; Deo Kumar Srivastava Journal: J Pain Symptom Manage Date: 2010-03 Impact factor: 3.612
Authors: Marilyn J Hockenberry; Mary C Hooke; Cheryl Rodgers; Olga Taylor; Kari M Koerner; Pauline Mitby; Ida Moore; Michael E Scheurer; Wei Pan Journal: J Pain Symptom Manage Date: 2017-04-20 Impact factor: 3.612
Authors: Yin Ting Cheung; Michelle N Edelmann; Daniel A Mulrooney; Daniel M Green; Wassim Chemaitilly; Neena John; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-06-26 Impact factor: 4.254
Authors: Shosha H M Peersmann; Martha A Grootenhuis; Annemieke van Straten; Wim J E Tissing; Floor Abbink; Andrica C H de Vries; Jacqueline Loonen; Helena J H van der Pal; Gertjan J L Kaspers; Raphaële R L van Litsenburg Journal: Cancers (Basel) Date: 2022-07-07 Impact factor: 6.575